Genmab A/S and its wholly owned subsidiary Genmab Finance LLC plan to raise $1.5 billion in senior secured notes due 2032 and $1.0 billion in senior unsecured notes due 2033, along with the syndication of a new $2.0 billion senior secured term loan "B" facility. These financing efforts, which build on previously syndicated credit facilities totaling $1.5 billion, are intended to fund the pending acquisition of Merus N.V., including related fees and expenses. Proceeds from the notes, new credit facilities, and existing cash will be used to cover the acquisition costs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001137979-en) on November 10, 2025, and is solely responsible for the information contained therein.